American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients

Simple item page
dc.contributor.authorCuker, Adam
dc.contributor.authorTseng, Eric K.
dc.contributor.authorNieuwlaat, Robby
dc.contributor.authorAngchaisuksiri, Pantep
dc.contributor.authorBlair, Clifton
dc.contributor.authorDane, Kathryn
dc.contributor.authorDavila, Jennifer
dc.contributor.authorDeSancho, Maria T.
dc.contributor.authorDiuguid, David
dc.contributor.authorGriffin, Daniel O.
dc.contributor.authorKahn, Susan R.
dc.contributor.authorKlok, Frederikus A.
dc.contributor.authorLee, Alfred Ian
dc.contributor.authorNeumann, Ignacio
dc.contributor.authorPai, Ashok
dc.contributor.authorRighini, Marc
dc.contributor.authorSanfilippo, Kristen M.
dc.contributor.authorSiegal, Deborah
dc.contributor.authorSkara, Mike
dc.contributor.authorTerrell, Deirdra R.
dc.contributor.authorTouri, Kamshad
dc.contributor.authorAkl, Elie A.
dc.contributor.authorAkl, Imad Bou
dc.contributor.authorBognanni, Antonio
dc.contributor.authorBoulos, Mary
dc.contributor.authorBrignardello-Petersen, Romina
dc.contributor.authorCharide, Rana
dc.contributor.authorChan, Matthew
dc.contributor.authorDearness, Karin
dc.contributor.authorDarzi, Andrea J.
dc.contributor.authorKolb, Philipp
dc.contributor.authorColunga-Lozano, Luis E.
dc.contributor.authorMansour, Razan
dc.contributor.authorMorgano, Gian Paolo
dc.contributor.authorMorsi, Rami Z.
dc.contributor.authorMuti-Schunemann, Giovanna
dc.contributor.authorNoori, Atefeh
dc.contributor.authorPhilip, Binu A.
dc.contributor.authorPiggott, Thomas
dc.contributor.authorQiu, Yuan
dc.contributor.authorRoldan, Yetiani
dc.contributor.authorSchuenemann, Finn
dc.contributor.authorStevens, Adrienne
dc.contributor.authorSolo, Karla
dc.contributor.authorWiercioch, Wojtek
dc.contributor.authorMustafa, Reem A.
dc.contributor.authorSchuenemann, Holger J.
dc.date.accessioned2025-01-20T22:05:58Z
dc.date.available2025-01-20T22:05:58Z
dc.date.issued2021
dc.description.abstractBackground: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE.
dc.description.abstractMethods: ASH formed a multidisciplinary guideline panel that included 3 patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process by performing systematic evidence reviews (up to 5 March 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update on guidelines published in February 2021.
dc.description.abstractResults: The panel agreed on 1 additional recommendation. The panel issued a conditional recommendation in favor of prophylactic-intensity over intermediate-intensity anticoagulation in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE.
dc.description.abstractConclusions: This recommendation was based on low certainty in the evidence, which underscores the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk.
dc.fuente.origenWOS
dc.identifier.doi10.1182/bloodadvances.2021005493
dc.identifier.eissn2473-9537
dc.identifier.issn2473-9529
dc.identifier.urihttps://doi.org/10.1182/bloodadvances.2021005493
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94179
dc.identifier.wosidWOS:000713028200005
dc.issue.numero20
dc.language.isoen
dc.pagina.final3959
dc.pagina.inicio3951
dc.revistaBlood advances
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleAmerican Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients
dc.typeartículo
dc.volumen5
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas